| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | See Remarks | Chief Operating Officer +1 more
1 company
Todd Bazemore last filed a Form 4 in October 2025, as Director at KALA. Todd Bazemore's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Todd Bazemore's trades have earned a strong insider score of 76/100 across 13 rated trades. Over a 12-month horizon, 76.9% of those trades were profitable, with an average 12-month return of +44.3%.
At the last filing, the largest reported position was 35,932 shares of KALA. The KALA filings lean toward selling, a net 77,595 shares.
Todd Bazemore has 31 Form 4 filings on record from November 2017 to October 2025, across 2 companies: Director at Kala Bio (KALA), 2017–2025; Director at Pulmatrix (PULM), 2020–2023.
The 49 reported transactions were 17 option or other derivative awards, 13 open-market sales, 8 stock awards and 8 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $58K and 13 sales worth about $176K.
The largest open-market purchase was 10,000 shares of KALA at an average $5.75 on March 16, 2020, about $58K.
The largest open-market sale was 47,768 shares of KALA at an average $0.83 on October 22, 2025, about $40K. Twelve months later KALA was down 100%.
None of the 7 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22, 2025 | KALA Kala Bio, Inc. | Director | Sell | 47,768 | $0.83 | $39,647.44 | -57.1% | -26.7% | -99.5% | |
| Jun 24, 2025 | KALA Kala Bio, Inc. | See Remarks | Sell | 4,058 | $4.01 | $16,272.58 | -4.6% | +363.8% | -25.0% | |
| Jun 3, 2025 | KALA Kala Bio, Inc. | See Remarks | Sell | 3,390 | $3.74 | $12,678.60 | -3.7% | +198.0% | -45.5% | |
| Jan 6, 2025 | KALA Kala Bio, Inc. | See Remarks | Sell | 1,993 | $7.63 | $15,206.59 | -100% | -50.3% | -91.3% | |
| Jun 26, 2024 | KALA Kala Bio, Inc. | See Remarks | Sell | 4,653 | $4.75 | $22,101.75 | -5.3% | +20.0% | +14.2% | |
| May 31, 2024 | KALA Kala Bio, Inc. | See Remarks | Sell | 2,093 | $6.09 | $12,746.37 | -2.3% | -12.4% | -44.6% | |
| Jan 4, 2024 | KALA Kala Bio, Inc. | See Remarks | Sell | 1,405 | $6.74 | $9,469.70 | -100% | +11.1% | +13.3% | |
| Jan 4, 2023 | KALA Kala Bio, Inc. | See Remarks | Sell | 62 | $28.54 | $1,769.48 | -0.4% | -67.0% | -83.4% | |
| Oct 26, 2022 | KALA Kala Bio, Inc. | See Remarks | Sell | 214 | $6.51 | $1,393.14 | -9.3% | +168.5% | +18.0% | |
| Jun 27, 2022 | KALA Kala Bio, Inc. | See Remarks | Sell | 3,092 | $0.37 | $1,144.04 | -2.6% | -37.2% | -11.6% |